No Data
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $165
BofA Securities analyst Tazeen Ahmad maintains $Ascendis Pharma A/S(ASND.US)$ with a buy rating, and maintains the target price at $165.According to TipRanks data, the analyst has a success rate of 46
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
European equities traded in the US as American depositary receipts fell Wednesday morning, declining 0.48% to 1,423.09 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led
Biopharma Leaders Shape the Future of Drug Development at Veeva R&D and Quality Summit Europe
Ascendis, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva to keynote sharing innovations to drive better patient outcomes BARCELONA, Spain, May 21, 2024 /PRNewswire/
$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 41.19% on an annualized basis producing an average annual return of 51.99%. Currently, Ascendis Pharma has a market
Damo: Maintaining the Ascendis Pharma (ASND.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $116.00 to $140.00.
Damo: Maintaining the Ascendis Pharma (ASND.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $116.00 to $140.00.
Morgan Stanley Maintains Equal-Weight on Ascendis Pharma, Raises Price Target to $140
Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Equal-Weight and raises the price target from $116 to $140.